Why the study?
Experimental studies revealed proinflammatory properties of angiotensin II, prompting evaluation of the antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and with pravastatin in patients with essential hypertension and microinflammation.
Does olmesartan medoxomil reduce vascular inflammation markers in patients with essential hypertension and microinflammation?
Does olmesartan medoxomil reduce vascular inflammation markers in patients with essential hypertension and microinflammation?
Angiotensin II receptor blockade with olmesartan significantly reduces vascular microinflammation in hypertensive patients, independent of blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Olmesartan reduces vascular inflammatory markers independent of BP effects in hypertension; extends evidence for pleiotropic ARB actions on microinflammation.
BACKGROUND: Experimental studies revealed proinflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin in patients with essential hypertension and microinflammation. METHODS AND RESULTS: We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein, and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure control was achieved with addition of hydrochlorothiazide. Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (-15.1%; P<0.05), high-sensitivity tumor necrosis factor-alpha (-8.9%; P<0.02), interleukin-6 (-14.0%; P<0.05), and monocyte chemotactic protein-1 (-6.5%; P<0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. After 12 weeks of therapy, high-sensitivity C-reactive protein (-21.1%; P<0.02), high-sensitivity tumor necrosis factor-alpha (-13.6%; P<0.01), and interleukin-6 (-18.0%; P<0.01) decreased further with olmesartan and pravastatin cotherapy, but treatment with pravastatin alone (ie, cotherapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin led to a significant (P<0.001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (-15.1% and -12.1%, respectively). CONCLUSIONS: Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. This antiinflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects.
No takes yet. Share an insight, caveat, or question.
Fliser et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: